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Keeping ahead of the resistance curve: product bundling to 
conserve artemisinin-based combination therapy
During recent years, malaria morbidity and mortality 
have substantially decreased.1,2 However, concurrently, 
resistance to artemisinin-based combination therapy 
and proliferation of substandard and counterfeit 
antimalarial drugs have continued to increase and 
subsequently threaten eﬀ ective malaria control.2–4 Here 
we suggest that bundling of rapid diagnostic tests 
with artemisinin-based combination treatment could 
address these two closely related problems. 
The global strategy to combat uncomplicated malaria 
relies on the widespread adoption of rapid diagnostic 
tests and the use of artemisinin-based combination 
treatment.2,3 Rapid diagnostic tests for malaria 
help with early and accurate diagnosis of infection 
(typically within 20 min) and are eﬀ ective, with high 
sensitivity (80–95%) and speciﬁ city (85%) in malaria-
endemic countries.2,5 The cost of a rapid diagnostic 
test ranges from US$0·45 for a Plasmodium falciparum 
test to $1·40 for an all-species test.4 Therefore, WHO 
guidelines recommend the use of these tests in these 
settings for the management of fever-like illness in 
children and adults.1,5
Antimalarials have large (although not well 
quantiﬁ ed) selection pressures on malaria parasites, and 
evolving resistance to artemisinin has been reported in 
southeast Asia with growing concern that resistance 
might spread.3 Additionally, the common practice of 
presumptive use of artemisinin-based combination 
treatment to treat fevers in many clinical settings 
inevitably leads to overuse.2,6 With few alternative 
treatment options available, the conservation of this 
treatment is important and thus improved stewardship 
is key to slowing down resistance.1,2,5,6
Bundling of medical products has been used 
successfully to improve health intervention delivery, 
as with the joint WHO-UNICEF policy statement on 
mass immunisation.7 The statement recommended the 
combination of vaccines, autodisposal syringes, and 
safety disposal boxes into one theoretical bundle for use 
in all mass-immunisation campaigns. A similar approach 
could conceivably be adapted for better antimalarial 
stewardship and include physical bundling of the two 
approaches for delivery to national control programmes.
The main aim of such a strategy would be to improve 
access to diagnostics and treatment while concurrently 
limiting excessive drug pressure in driving resistance 
through reductions in inappropriate prescription 
of artemisinin-based combination treatment. 
Bundled packages might also save costs for control 
programmes through fewer unnecessary prescriptions 
and more integrated diagnostic, treatment supply, 
and procurement chains. A bundling strategy would 
consist of three core elements: the alignment of 
ﬁ nancing mechanisms so that rapid diagnostic tests and 
artemisinin-based combination treatment can be funded 
and procured together; the epidemiological bundling 
based on local diagnostic and treatment needs; and the 
physical bundling of kits for delivery. This strategy might 
work well in public health care or pharmaceutical settings 
in which procurement and subsequent prescription of 
artemisinin-based combination treatment is subsidised 
or not directly linked to the income of the institution.
With wide variations in malaria endemicity, bundled 
packs would have to reﬂ ect the underlying epidemiology 
of target geographical areas. Ratios of rapid diagnostic 
tests to artemisinin-based combination treatment per 
pack would have to be adjusted to account for this as well 
as seasonal and treatment variations between paediatric 
and adult patient groups. In low transmission areas and 
seasons, several rapid diagnostic tests would be bundled 
per artemisinin-based combination treatment pack, and 
unused artemisinin-based combination components 
would be retained in storage until a positive rapid 
diagnostic test was obtained. In high transmission areas 
and seasons, fewer rapid diagnostic tests would need to be 
bundled per artemisinin-based combination treatment. 
For rare or unexpected aberrations in local or national 
epidemiology (eg, an unusually long rainy season 
or an unexpected outbreak), a central repository of 
limited numbers of 1:1 ratio bundles could be stored 
for rapid deployment. In the private sector, the use of 
bundled products has already started to grow, with 
several bundled products and schemes now available.8,9 
Concurrently, ﬁ nancing mechanisms, such as all-
inclusive pricing for testing and appropriate treatment 
are also being explored and evaluated.10
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Therefore, a standardised means of establishing the 
type and number of rapid diagnostic tests per treatment 
course of artemisinin-based combination treatment 
would need to be developed to support national malaria 
control programmes. The long product shelf-life of rapid 
diagnostic tests (18–24 months) means that worldwide 
mechanisms for supporting malaria control, such as 
Roll Back Malaria or the Global Fund, would be able to 
plan in advance how many bundles individual countries 
would require every year. This would support availability 
of an overall national supply that could be released 
periodically to account for local variations in incidence. 
The panel shows an example of how this might work in 
practice at a national level.
Illegal trade in counterfeit artemisinin-based 
combination treatment  is a major problem in Asia 
and Africa, and the subset of counterfeits containing 
substandard antimalarial compounds might contribute 
to driving antimalarial resistance.11 A cross-sectoral 
approach to illegal trade in counterfeit artemisinin-
based combination treatment requires public, political, 
legal, and ﬁ nancial interventions, and the adoption of 
novel technological solutions.11,12
Bundling could potentially contribute to combating 
counterfeit artemisinin-based combination treatment 
by adding extra layers of complexity and cost for 
counterfeiters (through the inclusion of a rapid 
diagnostic test in the pack). For example, the control line 
on the rapid diagnostic test strip would also have to be 
forged, hence when functional, could serve to reassure 
the patient and clinician that the bundled kit is genuine.
The next steps in exploring the feasibility of 
bundling rapid diagnostic tests with artemisinin-based 
combination treatment include broadening the 
debate by engaging policy makers, industry, and 
other stakeholders, and then pilot use in the public 
health-care sector as is already being done in the 
private sector.9 These pilot studies would have to 
show improved uptake of rapid diagnostic tests 
and a reduction in inappropriate prescription of 
artemisinin-based combination treatment. Ultimately, 
if eﬀ ective, sustainable economic models would need 
to be developed to increase equitable access. Therefore, 
improved stewardship through bundling of rapid 
diagnostic tests with artemisinin-based combination 
treatment cou ld be one important development in 
improving global malaria control. 
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Panel: How bundling might work at a national level—
supporting malaria control in Senegal
Senegal introduced rapid diagnostic tests for malaria in 2007 
and testing rates rose rapidly from 4% to 86% by 2009. 
Concurrently, the prescription of artemisinin-based 
combination treatment fell throughout the period, from 73% of 
malaria-like febrile illness to 32%—approximating quite closely 
the number of conﬁ rmed malaria cases. As a result, about 
500 000 unnecessary artemisinin-based combination treatment 
courses were avoided during the period.1 These data suggest 
that for planning purposes at a national level, a 3:1 ratio of rapid 
diagnostic testing to artemisinin-based combination treatment 
would be an appropriate bundling strategy for Senegal.
